close

  • home Home

  • linked_services Solutions keyboard_arrow_down

    • biotech Core Disciplines keyboard_arrow_down

      • View All
      • Quality Control
      • EQA
      • Chemistry
      • Immunoassay
      • Molecular
      • Point of Care
      • Toxicology
      • Food Diagnostics
      • BioSciences
      • BioReagents
      • Veterinary

    • neurology Disease Areas keyboard_arrow_down

      • View All
      • Acute Kidney Injury
      • Alzheimer's Disease
      • Chronic Kidney Disease
      • Chronic Lung Infection
      • Colorectal Cancer
      • Familial Hypercholesterolemia
      • Gastrointestinal
      • Hyperinflammation
      • Immunodeficiency
      • Neurovascular Dysfunction
      • Pancreatic Cancer
      • Urinary Tract Infection
      • Female Bladder Cancer Array
      • Acute Respiratory Distress Syndrome (ARDS)

    • store Online Store

  • experiment Services keyboard_arrow_down

  • support Support & Resources keyboard_arrow_down

  • apartment Company keyboard_arrow_down

    • Our Story
    • Our Vision
    • Our Team
    • Partners & Sponsorships
    • Charity Partners
    • Collaborators
    • Careers

  • mail Contact

  • Solutions
    keyboard_arrow_down
  • Services
    keyboard_arrow_down
  • Support & Resources
    keyboard_arrow_down
  • Company
    keyboard_arrow_down
  • Contact
Randox Health search menu
Randox Health search

Get in touch to discover more

To find out more about the Metabolic Dysfunction-Associated, enquire now.

Make an Enquiry mail
download Download whitepaper

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formally known as Non-Alcoholic Fatty Liver Disease (NAFLD), is a prevalent liver disease that affects people worldwide. It is more common in males than females, with an estimated global incidence of 47 cases per 1,000 population. Among adults, the global prevalence of MASLD is estimated to be 32%, with a higher prevalence among males (40%) than females (26%).

It is predicted to be the most frequent indication for liver transplants. MASLD occurs due to an ectopic accumulation in hepatocytes, which causes insulin resistance, chronic inflammation, progressive fibrosis, and an increased risk of hepatocellular carcinoma. Currently, the diagnosis of MASLD is made by ultrasound, and an invasive biopsy is needed for staging.

Biochip Markers

IL-6IL-8PIIINP
ST2/IL-33RTNF-α

Benefits of the Evidence MultiSTAT

ward Improved Triage

Using biomarker data would improve triage, reduce or defer referral, fast track patients identified as 'high risk', and reduce healthcare burden.

savings Save Hospital Resources

With results from a single sample patients can avoid taking unnecessary and invasive tests

data_array Better Patient Care

Biochip results and refined data-based analysis accelerates medical decisions.

The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple biomarkers.

Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.

With minimal sample preparation required, this versatile benchtop analyser can achieve accurate, quantitative results in minutes.

MultiSTAT brochure  download

MultiSTAT Cartridge

The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.

The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.

No other components are required.